Erigeron breviscapus: A Promising Medication for Protecting the Optic Nerve in Glaucoma.

IF 2.1 4区 医学 Q3 CHEMISTRY, MEDICINAL
Planta medica Pub Date : 2024-09-20 DOI:10.1055/a-2409-2999
Yuxin Cheng, Xuanyi Chen, Guangyu Zhu, Na Li, Yue Sun, Shichun Luo, Yujie Liu, Xuejing Lu
{"title":"Erigeron breviscapus: A Promising Medication for Protecting the Optic Nerve in Glaucoma.","authors":"Yuxin Cheng, Xuanyi Chen, Guangyu Zhu, Na Li, Yue Sun, Shichun Luo, Yujie Liu, Xuejing Lu","doi":"10.1055/a-2409-2999","DOIUrl":null,"url":null,"abstract":"<p><p>Glaucoma is a common eye condition characterized by the loss of retinal ganglion cells and their axons, optic nerve damage, and visual field defects, which seriously affect a patient's quality of life. The pathogenesis of glaucoma is still unclear at present. It presents as damage to retinal ganglion cells, and the main treatment is primarily to reduce intraocular pressure by surgery or taking medication. However, even with well-controlled intraocular pressure, retinal ganglion cells still undergo degeneration, progressive apoptosis, and axonal loss. Therefore, protecting the optic nerve and inhibiting the apoptosis of retinal ganglion cells are the current hot topic for prevention and treatment of glaucoma. Recently, <i>Erigeron breviscapus</i>, originating from Yunnan province in China, has been shown to be a promising herb with neuroprotective effects to treat glaucoma. Therefore, the traditional usage, botanical characteristics, and phytochemical composition of <i>E. breviscapus</i> were explored through a literature review. Furthermore, we have summarized the pharmacological mechanisms of <i>E. breviscapus</i> and its active components in inhibiting the apoptosis of retinal ganglion cells. These research findings can not only provide guidance and recommendations for the protection of retinal ganglion cells but also further explore the potential of <i>E. breviscapus</i> in the treatment of glaucoma.</p>","PeriodicalId":20127,"journal":{"name":"Planta medica","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Planta medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2409-2999","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Glaucoma is a common eye condition characterized by the loss of retinal ganglion cells and their axons, optic nerve damage, and visual field defects, which seriously affect a patient's quality of life. The pathogenesis of glaucoma is still unclear at present. It presents as damage to retinal ganglion cells, and the main treatment is primarily to reduce intraocular pressure by surgery or taking medication. However, even with well-controlled intraocular pressure, retinal ganglion cells still undergo degeneration, progressive apoptosis, and axonal loss. Therefore, protecting the optic nerve and inhibiting the apoptosis of retinal ganglion cells are the current hot topic for prevention and treatment of glaucoma. Recently, Erigeron breviscapus, originating from Yunnan province in China, has been shown to be a promising herb with neuroprotective effects to treat glaucoma. Therefore, the traditional usage, botanical characteristics, and phytochemical composition of E. breviscapus were explored through a literature review. Furthermore, we have summarized the pharmacological mechanisms of E. breviscapus and its active components in inhibiting the apoptosis of retinal ganglion cells. These research findings can not only provide guidance and recommendations for the protection of retinal ganglion cells but also further explore the potential of E. breviscapus in the treatment of glaucoma.

Erigeron breviscapus:保护青光眼视神经的有效药物
青光眼是一种常见的眼科疾病,其特点是视网膜神经节细胞及其轴突缺失、视神经损伤和视野缺损,严重影响患者的生活质量。目前,青光眼的发病机制尚不清楚。它表现为视网膜神经节细胞受损,主要治疗方法主要是通过手术或服药降低眼压。然而,即使眼压控制得很好,视网膜神经节细胞仍会发生变性、进行性凋亡和轴突丢失。因此,保护视神经、抑制视网膜神经节细胞凋亡是当前预防和治疗青光眼的热门话题。最近,原产于中国云南省的麦冬被证明是一种具有神经保护作用的草药,可用于治疗青光眼。因此,我们通过文献综述探讨了马钱子的传统用法、植物学特征和植物化学成分。此外,我们还总结了马钱子及其活性成分抑制视网膜神经节细胞凋亡的药理机制。这些研究成果不仅能为保护视网膜神经节细胞提供指导和建议,还能进一步挖掘马钱子草在治疗青光眼方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Planta medica
Planta medica 医学-药学
CiteScore
5.10
自引率
3.70%
发文量
101
审稿时长
1.8 months
期刊介绍: Planta Medica is one of the leading international journals in the field of natural products – including marine organisms, fungi as well as micro-organisms – and medicinal plants. Planta Medica accepts original research papers, reviews, minireviews and perspectives from researchers worldwide. The journal publishes 18 issues per year. The following areas of medicinal plants and natural product research are covered: -Biological and Pharmacological Activities -Natural Product Chemistry & Analytical Studies -Pharmacokinetic Investigations -Formulation and Delivery Systems of Natural Products. The journal explicitly encourages the submission of chemically characterized extracts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信